Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%
Market cap
$13.8B
P/E
34.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
25.79 13.66 17.47 37.25 14.11 44.49 0.00 0.00 50.50 0.00
Piotroski F-Score
5 9 8 4 5 7 3 3 7 2
P/S ratio
5.77 5.97 5.95 11.43 12.76 21.74 13.06 13.83 8.70 8.71
Altman Z-Score
3.46 4.31 3.41 4.14 5.77 8.55 2.67 5.48 5.91 (0.12)
P/FCF ratio
12.51 12.95 13.21 28.87 18.98 107.68 0.00 0.00 20.77 0.00
Altman Z″-Score (non-manufacturers)
3.02 5.60 3.93 3.50 6.54 0.88 1.23 0.52 3.26 (4.49)
Beneish M-Score
(2.59) (2.33) (2.74) (0.57) 0.26 (1.25) (1.56) (1.35) (0.87) (4.61)
P/Operating CF
36.82 33.98 48.19 91.50 68.54 114.25 (96.11) 200.81 17.98 (81.08)
P/B ratio
165.22 16.67 58.86 44.43 28.71 38.51 27.89 8.44 13.23 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00 28.71 38.51 27.89 8.44 13.23 0.00
EV/Sales
7.72 6.90 7.39 13.16 13.06 23.32 12.96 12.33 7.86 8.79
EV/EBITDA
19.20 11.13 14.47 26.64 20.33 38.40 0.00 0.00 29.41 0.00
EV/Operating CF
16.54 14.62 15.77 36.18 19.34 112.53 (29.74) (37.83) 18.57 (25.60)
EV/FCF
16.72 14.96 16.42 33.25 19.43 115.50 (28.39) (34.58) 18.75 (24.10)
Quick Ratio
3.30 6.50 5.07 4.54 7.10 1.11 5.61 2.57 3.74 4.04
Current Ratio
4.66 7.80 6.64 5.65 7.91 1.32 6.35 2.86 3.89 4.70
Net Debt/EBITDA
3.56 1.45 2.75 3.51 0.48 0.18 0.29 3.33 (3.15) (0.17)
Debt/Assets
84.85% 72.97% 86.50% 81.79% 79.38% 68.50% 71.14% 28.71% 38.92% 82.83%
Debt/Equity
43.89 4.14 17.89 8.87 4.45 2.63 4.39 0.51 0.97 (6.67)
Asset Turnover
0.61 0.53 0.46 0.45 0.53 0.47 0.39 0.32 0.81 0.66
Operating CF/Net income
2.06 1.08 1.38 1.19 0.74 0.43 1.18 0.62 2.13 0.49
Capex/Depreciation
(0.08) (0.14) (0.18) 0.36 (0.16) (0.08) (0.99) (5.53) (0.37) (0.20)
Interest Coverage
25.87 30.48 17.99 15.79 36.66 7.08 (5.81) (3.84) 3.68 (4.17)
ROE
153.59% 198.42% 222.07% 110.23% 231.44% 106.33% (42.41%) (35.14%) 71.60% (1,958.98%)
ROA
13.81% 23.39% 15.75% 13.72% 47.82% 22.53% (14.36%) (16.73%) 16.12% (46.48%)
ROIC
14.31% 27.06% 16.92% 12.73% 51.83% 50.02% (57.81%) (208.92%) 0.00% 0.00%
Return on Tangible Assets
43.39% 43.48% 39.72% 29.56% 49.24% 89.66% (15.41%) (28.09%) 16.46% (49.96%)
Average Days of Receivables
115.33 110.89 103.09 127.77 74.90 133.30 110.70 72.12 25.52 39.02
Research and Development Expense of Revenue
26.23% 7.79% 9.21% 10.09% 8.05% 12.79% 71.84% 98.94% 47.58% 102.83%
Selling, General and Administrative Expense of Revenue
14.83% 15.20% 17.99% 21.74% 11.35% 17.09% 39.42% 40.04% 17.00% 31.26%
Intangible Assets out of Total Assets
0.62 0.40 0.51 0.52 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
3.69% 4.27% 4.42% 3.70% 4.70% 6.43% 17.74% 23.51% 9.69% 17.44%
Graham Net Nets
(0.20) (0.10) (0.18) (0.12) 0.00 0.02 0.03 0.11 0.07 (0.03)
Graham Number
4.89 15.03 5.53 6.43 9.48 4.89 0.00 0.00 3.71 2.15
Earnings Yield
3.88% 7.32% 5.72% 2.68% 7.09% 2.25% (2.82%) (3.79%) 1.98% (8.11%)
Free Cash Flow Yield
7.99% 7.72% 7.57% 3.46% 5.27% 0.93% (3.50%) (2.58%) 4.82% (4.19%)
Revenue per Share
11.65 8.01 6.29 4.82 3.15 1.96 1.36 1.06 2.32 1.15
Operating CF per Share
5.44 3.78 2.95 1.75 2.13 0.41 (0.59) (0.34) 0.98 (0.39)
Capex per Share
(0.06) (0.08) (0.12) 0.15 (0.01) (0.01) (0.03) (0.03) (0.01) (0.02)
Free Cash Flow per Share
5.38 3.69 2.83 1.91 2.12 0.40 (0.62) (0.38) 0.97 (0.42)
Cash per Share
1.19 4.70 2.55 2.65 5.27 2.70 2.92 2.47 3.44 1.60
Shareholders Equity per Share
0.41 2.87 0.64 1.24 1.40 1.11 0.64 1.73 1.53 (0.25)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.41 2.87 0.64 1.24 1.40 1.11 0.64 1.73 1.53 (0.25)
Free Cash Flow
644.59 468.37 373.28 261.31 297.98 54.03 (89.46) (54.16) 132.70 (53.52)
Working Capital
648.12 946.24 633.93 608.22 809.14 133.38 457.80 278.49 379.04 201.95
Capital Expenditures
(6.97) (10.70) (15.29) 21.20 (1.46) (1.43) (4.04) (4.66) (1.35) (3.14)
Net Current Asset Value
(1,651.30) (614.32) (903.04) (932.70) 18.81 125.89 69.33 236.49 198.79 (37.46)
EV/EBIT
22.98 12.70 18.15 32.47 20.99 43.26 0.00 0.00 30.73 0.00
Capex to Sales
0.01 0.01 0.02 (0.03) 0.00 0.01 0.02 0.03 0.00 0.02
Price to Operating Income
17.20 11.00 14.61 28.20 20.50 40.33 0.00 0.00 34.02 0.00
Other line items
Depreciation/Fixed assets
1.12 1.04 1.15 0.78 1.01 1.72 0.38 0.11 1.03 3.66
Cash ROIC
27.61% 19.00% 19.45% 12.82% 16.42% 5.90% (9.77%) (7.42%) 15.08% (13.75%)
Accounts Receivable Turnover
3.73 3.74 3.56 4.10 4.70 3.41 4.38 5.83 16.75 6.10
Accounts Payable Turnover
14.69 14.45 13.04 14.49 46.94 10.37 8.66 1.69 5.41 8.22
Inventory Turnover
1.44 1.18 1.69 1.81 1.42 0.96 1.75 0.73 3.15 2.75
Average Days of Payables
33.34 23.47 22.42 46.36 6.91 16.23 51.56 146.89 93.12 39.33
Days of Inventory on Hand
281.56 324.80 242.12 262.34 241.69 511.28 235.28 814.73 60.29 160.74
Average Receivables
374.86 271.33 232.64 161.02 94.35 78.59 44.72 26.07 18.91 24.05
Average Payables
15.57 11.03 14.75 9.62 1.73 4.18 5.26 6.01 5.76 4.04
Average Inventory
159.17 134.73 113.86 77.02 57.33 45.05 25.99 13.89 9.88 12.06
Average Assets
2,294.40 1,898.37 1,787.39 1,472.97 842.18 572.90 503.06 480.10 390.73 221.65
Average Common Equity
206.32 223.81 126.80 183.38 174.00 121.41 170.33 228.63 87.94 5.26

Fold the line items

Columns are period end dates